SCHEMBL569669

SCHEMBL569669

O=CN(CCCCCCNS(=O)(=O)c1ccc(Oc2ccccc2)cc1)P(=O)(O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.64
CA2 P00918 6/20 0.64
CA9 Q16790 6/20 0.64
CA12 O43570 5/20 0.64
CA1 P00915 5/20 0.64
ADAMTS4 O75173 2/20 0.50
MMP13 P45452 2/20 0.50
MMP14 P50281 2/20 0.50
ADAMTS5 Q9UNA0 2/20 0.50
ALDH1A1 P00352 4/20 0.48
PKM P14618 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MMP1 P03956 1/20 0.46
MEP1B Q16820 1/20 0.46
TBXA2R P21731 1/20 0.44
NPY1R P25929 1/20 0.43
NPY5R Q15761 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569863 1.00 MMP2 (0.64) MMP2CA2CA9CA12CA1
SCHEMBL569312 0.99 MMP2 (0.64) MMP2CA2CA9CA12CA1
SCHEMBL569539 0.95 MMP2 (0.61) MMP2CA2CA9CA12CA1
SCHEMBL570168 0.91 MMP2 (0.60) MMP2CA2CA9CA12CA1
SCHEMBL570026 0.86 MMP2 (0.53) MMP2CA2CA9CA12CA1
SCHEMBL569548 0.86 MMP2 (0.53) MMP2CA2CA9CA12CA1
SCHEMBL569309 0.85 CA12 (0.46) MMP2CA2CA9CA12CA1
SCHEMBL569753 0.84 MMP2 (0.52) MMP2CA2CA9CA12CA1
SCHEMBL568568 0.81 MMP2 (0.50) MMP2CA2CA9CA12CA1
SCHEMBL568909 0.78 MMP2 (0.66) MMP2CA2CA9CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993544-B2 Carbamoylphosphonates as inhibitors and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2015-03-31 US disclosed
EP-2393495-B1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RES DEV CO (IL) 2014-07-23 EP disclosed
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-02-09 US disclosed
EP-2393495-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2011-12-14 EP disclosed
WO-2010089752-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF MMP9, MMP26, MMP25 MMP2 10/4885CA2 91/4885CA9 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.